This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The biotech’s transition from drugdelivery specialist to maker of novel medicines led to competing neuroscience and oncology divisions. The latter will soon become a separate company.
This intersection will be remembered as one of the most significant achievements in science and medicine”. The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drugdelivery. Lipid nanoparticle drugdelivery was in the spotlight during the Covid-19 pandemic.
Medicine has been delivered by inhalation for decades to treat human respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and airway infection. Why is pulmonary drugdelivery a complex challenge? How can we accomplish drugdelivery to the lungs in nonclinical studies?
Drugdelivery technology is aimed at helping people with spinal cord and other nervous system disorders Credit: KiBum Lee, Letao Yang and Brian M. The system, […].
Sixfold Bioscience and Medicines Discovery Catapult awarded Innovate UK grant to pursue ground-breaking project. Programmable Oligonucleotide Delivery System (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.
Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 for each share in cash. The deal comprises an acquisition value of $12.50 AK-OTOF is the lead product candidate of the company.
Texas A&M associate professor Akhilesh Gaharwar and graduate student Patrick Lee are developing a new class of hydrogels that can leverage light for drugdelivery and regenerative medicine treatments. However, once inside, they can be challenging […].
— University of Louisville researchers have found a less toxic way to deliver medicines by using the natural lipids in plants, particularly grapefruit and ginger. Suite of technologies now has commercial partner to bring them to market Credit: University of Louisville LOUISVILLE, Ky.
A mutual symbiotic relationship is formed between the two domains, where with the help of technology new discoveries can be made in the field of medicine for the sole purpose of helping people. AI is able to mine records, design treatment studies, find out targets of drugdelivery in a way more drastic manner than a human can.
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drugdelivery technology to enable development of “ultra long-acting” medicines for HIV ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drugdelivery technology to … Continue reading →
Therefore, medical technology is rapidly evolving, enabling more advanced and patient-friendly methods of drugdelivery. In the pursuit of creating patient-centric healthcare solutions, the medical industry has witnessed a groundbreaking advancement in drugdelivery with the emergence of large volume wearable injectors.
Orbis Medicines secures 90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to biologic drugs and targeting chronic disease markets.
XTALKS : Changes are Coming to Prefilled Injectable DrugDelivery Systems Live and On-Demand: Thursday, September 12, 2024, at 1pm EDT (10 am PDT) Register for this webinar today to learn more about the future of injectable drugdelivery systems and the impact of blow-fill-seal technology.
Lakhan, is an inventive entrepreneurial physician-scientist who is board-certified in neurology and pain medicine with over 20 years of industry experience. As Chief Medical and Scientific Officer at Click Therapeutics and a Board Director at SpineThera, he spearheads AI-enabled clinical development and drug-delivery platforms.
– Before the huge potential of tiny nanocarriers for highly targeted drugdelivery and environmental clean-up can be realized, scientists first need to be able to see them. Credit: Washington State University PULLMAN, Wash.
– Scientists used human white blood cell membranes to carry two drugs, an antibiotic and an anti-inflammatory, directly to infected lungs in mice. The nano-sized drugdelivery method developed at Washington State University successfully treated both the bacterial growth and inflammation in the mice’s lungs.
Elyxyb is a prescription nonsteroidal anti-inflammatory drug (NSAID) used for acute migraine treatment in adult patients with or without aura. It is formulated using a self-micro-emulsifying drugdelivery system that improves the drug’s bioavailability and solubility.
Dill/NIST In a technique known as DNA origami, researchers fold long strands of DNA over and over again to construct a variety of tiny 3D structures, including miniature biosensors and drug-delivery containers.
Federally funded study says drugdelivery for certain common eye diseases could be improved Credit: University of Cincinnati Getting poked in the eye with a sharp object is a cringeworthy thought.
Theresa Heah is the CEO of Intergalactic Therapeutics, bringing over two decades of global leadership experience in ophthalmology drug development along with commercialization in early-stage, private-staged companies. We spoke to her about her background, overcoming adversity and unlocking the power of science.
The digital therapeutics specialist has announced the last patient has ended participation in a study investigating a precision solution for hypertension.
London, UK, 28 June 2023 / Sciad Newswire / Hosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.
AGC Biologics stated that present research at the Jikei University School of Medicine revealed the important role that extracellular vesicles can play in IPF pathogenesis. Researchers there will identify proof of concept, as well as the viability of developing a prototype of an exosome-based treatment derived from bronchial epithelial cells.
Robotics, for example, has facilitated the automation of medicine preparation and distribution, controlled drugdelivery systems, and machine-readable coding on medicine packages. Newly emerging technologies have helped in improving the effectiveness and safety of non-sterile commercial dose products.
This morning, Sandoz announced it has acquired medical and drugdelivery device specialist Coalesce Product Development, bolstering its capabilities for the development of respiratory medicines and ‘complex’ generics.
The UK Government has announced plans to allow patients in England to receive prescription medicines directly from pharmacies without the need for a GP appointment.
If these hollow capsules are modified to target a solid tumor, PET imaging and therapeutic ultrasound can be used to rupture them and release an anticancer drug at ground zero. Credit: UAB BIRMINGHAM, Ala.
Linker Stability : The stability of the linker, which attaches the chemotherapy agent to the antibody, is essential for efficient and precise drug-delivery. Researchers are actively looking for ways to solve these problems with the goal of finding the optimal balance between efficacy and toxicity for many of these drugs.
Researchers at ETH Zurich have developed a method for concentrating and releasing drugs in the brain with pinpoint accuracy. This could make it possible in the future to deliver psychiatric and cancer drugs and other medications only to those regions of the brain where this is medically desirable.
Evotec and Chinook Therapeutics have collaborated to develop and discover precision medicine therapies for patients with chronic kidney diseases (CKD). The duo plans to jointly identify, characterize and validate novel mechanisms and discover and develop precision medicines. HitGen & UPPTHERA Collaborate for DrugDelivery Research.
Key Growth Drivers Autoinjectors Market Ease of Use: The benefits of using autoinjectors over conventional methods of parenteral drugdelivery are widely recognized by healthcare industry professionals as well as end-users.
The partners intend to use the connected technology on self-administered medicines like biologics, to capture and transmit injection data and monitor patients’ adherence with therapy.
Scientists have established a new method to image proteins that could lead to new discoveries in disease through biological tissue and cell analysis and the development of new biomaterials that can be used for the next generation of drugdelivery systems and medical devices.
(“CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. Cyto-111 was conceived, expressed and purified in the laboratory of Konstantin Ichtchenko, Ph.D., Südhof, M.D., Band, Ph.D.,
One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.
But with the advent of injection site absorption enhancers, drugdelivery device innovations, as well as the recent primary container options, the practical subcutaneous self-administration of large-volume parenterals is becoming possible. National Library of Medicine – Silicone Oil Induced Aggregation of Proteins 4.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content